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Osteosarcoma (OS) is the most common nonhematologic malignancy of bone in children and adults. Although dysregulation
of tumor suppressor genes and oncogenes, such as Rb, p53, and the genes critical to cell cycle control, genetic stability, and
apoptosis have been identiﬁed in OS, consensus genetic changes that lead to OS development are poorly understood. Disruption
of the osteogenic diﬀerentiation pathway may be at least in part responsible for OS tumorigenesis. Current OS management
involves chemotherapy and surgery. Peroxisome proliferator-activated receptor (PPAR) agonists and/or retinoids can inhibit OS
proliferation and induce apoptosis and may inhibit OS growth by promoting osteoblastic terminal diﬀerentiation. Thus, safe and
eﬀective PPAR agonists and/or retinoid derivatives can be then used as adjuvant therapeutic drugs for OS therapy. Furthermore,
these agents have the potential to be used as chemopreventive agents for the OS patients who undergo the resection of the primary
bone tumors in order to prevent local recurrence and/or distal pulmonary metastasis.
1.Introduction
Osteosarcoma (OS) is the most common nonhematologic
malignant tumor of bone in adults and children, with the
peak incidence in early childhood [1, 2]. It is associated
with a poor prognosis due to its high grade at presentation,
resistance to chemotherapy, and propensity to metastasize
to the lungs [3, 4]. Furthermore, while 80% of OS patients
are believed to have micrometastatic disease, only 10%–
15% present as radiographically detectable lesions [5, 6].
Herein lies the challenge in identifying the 20% OS patients
without micrometastases and modifying medical and sur-
gical management accordingly. Genetic markers associated
with metastatic disease could potentially spare those patients
that need for chemotherapeutic agents, such as adriamycin,
cisplatin,ormethotrexate,andexperienceitsseveretoxicities
ranging from cardiotoxicity to renal dysfunction.
It has been shown that OS cells are similar to undiﬀer-
entiated osteoblasts, and increasing evidence suggests that
osteogenic diﬀerentiation defects may be responsible for
OS tumorigenesis [2, 7–10]. Osteoblasts are derived from
mesenchymal stem cells (MSCs), and osteoblastic diﬀeren-
tiation is a tightly regulated process by numerous growth
and diﬀerentiation factors, such as bone morphogenetic
proteins (BMPs) and Wnts [2]( Figure 1). It is conceivable
that any disruption of osteogenic terminal diﬀerentiation
may result in the development of OS. The aggressiveness
of OS may depend on the stage of disruption; that is,
more aggressive OS phenotypes may be developed from
mutant early osteoblast progenitors, whereas benign tumors
may arise from disruptions of late stage osteoblasts [2, 7]
(Figure 2).
Current cancer therapies primarily target the prolifera-
tive compartment of tumor cells. While eﬀective in initial
treatment, these strategies are often nulliﬁed by subsequent
drug resistance. An attractive alternative is to overcome the
uncontrolled cell proliferation through promoting terminal
diﬀerentiation [8, 9, 11–13]. One possibility deals with2 PPAR Research
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Figure 1: Osteogenic and adipogenic diﬀerentiation pathways in mesenchymal stem cells (MSCs). MSCs are pluripotent progenitor cells
that are able to diﬀerentiate into several lineages, including osteogenic and adipogenic lineages, upon the stimulation with distinct growth
and diﬀerentiation cues. The lineage-speciﬁc diﬀerentiation is a multiple-stage and well-coordinated process regulated by master regulators,
such as PPARγ and C/EBPβ for adipogenesis and Runx2 and Osterix for osteogenesis. Osteogenic diﬀerentiation can be staged by measuring
alkaline phosphatase (early marker) and osteocalcin and osteopontin (late markers). Expression of FABPs and production of lipids are
indicators of terminal adipogenic diﬀerentiation.
the use of agonists or antagonists of the nuclear receptor
superfamily, including vitamin D3, thyroid hormone, glu-
cocorticoids, sex hormones, retinoids, and orphan receptors
[14–18]. One interesting subgroup of the nuclear receptor
superfamily is peroxisome proliferator-activated receptors
(PPARs), which play a role in both promoting tumorige-
nesis and inducing terminal diﬀerentiation and apoptosis.
Antitumor activity of PPARγ agonists has been shown in
tumor cells derived from liposarcoma, colon cancer, breast
cancer, leukemia, gastric cancer, nonsmall cell lung cancer,
and prostate cancer [19–31]. Furthermore, PPARγ agonists
have the potential to induce terminal diﬀerentiation in
osteosarcoma cells [2, 9, 32]. In this review, we focus
on the functional role of PPARs and their cross-talk with
other nuclear receptors in osteogenic diﬀerentiation and
tumorigenesis and the potential use of PPARγ agonists
as chemotherapeutic and/or chemopreventive agents for
human OS.
2.PPARs andTheir Ligands
PPARs are ligand-activated transcription factors that achieve
functionality after forming a heterodimer with the 9-cis
retinoid X receptor (RXR). The subsequent transcriptional
activity is modulated by nuclear receptor coactivators and
corepressors [33], such as C/EBP PGC1 (α/β), PRIP, N-Cor,
SRC-1, p300, Hsp-72, and PBP [34–39]. The ligands include
the synthetic thiazolinediones and ﬁbrates and endogenous
fatty acids and eicosanoids [40, 41]. Upon ligand binding
and heterodimerization with RXR, PPARs recognize PPAR
response elements (PPREs) containing the direct repeat
sequence (DR-1) AGGTCA [33, 34]. PPARs can also repress
genetranscriptionthroughinterferingwithNFκB, STAT, and
AP-1 signaling pathways [41–43]. Three subtypes of PPARs
have been identiﬁed, PPARα,P P A R β,a n dP P A R γ [16, 44].
PPARαisfoundinliver,brownfat,kidney, heart,andskeletal
muscle. PPARβ (also known as PPARδ) is expressed in the
gut, kidney, brain, skeletal muscle, and heart [34, 45]. PPARγ
is expressed primarily in adipose tissue and to a lesser extent
in large intestine, kidney, prostate, cartilage, osteoblasts,
epithelial cells, and monocytes [46].
PPARs play a role in diabetes, atherosclerosis, obe-
sity, the inﬂammatory response, and cancer [47]. PPARs
regulate the expression of many genes associated with
lipid storage, β-oxidation of fatty acids, terminal dif-
ferentiation of preadipocytes, and modulation of the
body’s response to insulin and glucocorticoids [16, 47–50].
PPARα functions primarily in lipid catabolism, lipoprotein
metabolism, and inﬂammation, as its expression increases
with stress, glucocorticoid expression, exercise, and fasting
[47, 51, 52]. PPARα knockouts develop normally, however,
exhibit hepatomegaly from lipid accumulation and liver
tumors, impaired wound healing, prolonged inﬂammatory
responses, and increased adipose tissue [53]. PPARβ has a
relatively diverse range of functions, including β-oxidation
of fats, tumorigenesis [54], vascular integrity [55], and bonePPAR Research 3
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Figure 2: Osteosarcoma (OS) development and nuclear receptor agonist-mediated diﬀerentiation therapy. OS can be regarded as a
diﬀerentiation disease, which is caused by disruptions of the terminal osteogenic diﬀerentiation. The stage and nature of diﬀerentiation
defects may determine the aggressiveness of OS tumors. PPARγ agonists and/or retinoids have been shown to inhibit OS proliferation,
induce apoptosis, and promote osteogenic diﬀerentiation. Thus, these agents can be used as diﬀerentiation therapy, in combination with
conventional chemotherapy, for OS treatment.
metabolism [16]. PPARβ knockouts have fatal placental
defects secondary to abnormal vascular development, and
those that survive become small, but healthy adults [53].
PPARγ aﬀects the storage of fatty acids in adipose tissue,
whilealsoopposingTNFαandIL-6productionininﬂamma-
tory responses and insulin sensitization [47, 49, 50, 56, 57].
PPARγ knockouts are embryo-lethal as the placenta fails
to implant and develop properly, and those that survive
display severe metabolic, intestinal, hepatic, and adipogenic
abnormalities [53].
3. Formation of PPAR and RXR Heterodimeric
Receptor Complexes
PPARsconsistof4domains,AB,C,D,andE.TheABdomain
function has not been clearly elucidated. The C domain
represents the DNA binding domain (DBD), whereas the
D domain contains the DBD carboxyl group along with
the hinge connecting the C and E domains. The E domain
(LBD) has a variety of functions, including ligand binding,
hormone transactivation, and dimerization interface [16, 34,
45]. The three-dimensional structure of the LBD domain is
very well conserved amongst the thyroid hormone receptor
(TRα1), retinoic acid receptor (RAR), and retinoid X
receptor (RXR) [58–60]. RXR is a promiscuous receptor
and able to heterodimerize with RAR, PPAR, VDR, TR,
and orphan receptors. This enables the competition among
multiple hormones and other ligands to exert a variety of
eﬀects within the same tissue. It has been demonstrated that
high concentrations of thyroid hormone inhibit the ability
of PPARγ to heterodimerize with RXR and, therefore, blocks
transcriptional activation (Figure 3)[ 61]. Transrepression
occurs through sequestration of the coactivators CBP and
SRC-1 by the PPAR/RXR heterodimers, preventing their
utilization in other signaling pathways [62].
A unique association with PPAR and RXR is the direct
repeat responsive elements (DR) and the PPAR response
elements (PPRE) associated with the heterodimer. DR1
is a repetition of 2 core motifs consisting of AGGTCA
spaced apart from one another by one nucleotide in the
promoter of multiple target genes (Figure 3)[ 63]. These
motifs are recognized by two zinc ﬁnger-like motifs in
the DBD region of PPAR. These PPREs produced by the
PPAR:RXR heterodimer are diﬀerent from those recognized
by the vitamin D receptor (DR3), thyroid hormone receptor
(DR4), and retinoic acid receptor (DR2, DR5) [34, 64,
65]. The importance of PPARγ:RXR interaction is seen in
Familial Partial Lipodystrophy, an autosomal dominant con-
dition associated with metabolic syndrome, characterized by
dyslipidemia, abnormal adipose tissue distribution, and a
number of metabolic abnormalities [66]. This syndrome is
associatedwithmultiplemissenseandnonsensemutationsof
PPARγ that aﬀect its ability to dimerize with RXR and bind
coactivators.4 PPAR Research
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Figure 3: Current mode of action for PPARγ.P P A R γ and RXR form a heterodimer, which is activated by the respective ligands. The
activated PPARγ/RXR heterodimer will be translocated into nucleus and regulates downstream target genes in concert with nuclear receptor
coactivators.
4. DiverseFunctionsof PPARγ
PPARγ is of particular interest because of its roles in
adipogenesis, atherosclerosis, inﬂammation, proliferation,
diﬀerentiation,andapoptosis[67].ThePPARγ genecontains
3 promoters, producing 2 diﬀerent proteins, PPARγ1a n d
PPARγ2, which likely contributes to this diverse range of
functions [55]. PPARγ expression in vascular endothelium
and smooth muscle cells leads to an inhibition of MMPs,
downregulation of Angiotensin II type 1 receptor, and
alteration of macrophage invasion [68–71]. In inﬂammatory
responses, its strongest association occurs with the ligand
prostaglandin J2 (PGJ2) [16, 42, 72]. This eicosanoid
metabolite binds directly to PPARγ, leading to its activation
in the inﬂammatory response cascade. Furthermore, the
insulin sensitizing eﬀects of PPARγ are demonstrated using
the synthetic antidiabetic therapy thiazolinediones [42, 72,
73]. Thus, the promiscuity of its ligand binding and a variety
of associated nuclear proteins enables the diversity of PPARγ
functions in many tissues.
For adipogenesis, PPARγ binds to fatty acids and their
derivatives, such as linoleic acid and docosahaxaenoic acid
(DHA) [34, 43]. These ligands activate PPARγ, stimulating
preadipocytes to diﬀerentiate and initiate the steps required
in lipid storage. PPARγ eﬀects are carried out through
target genes, such as aP2, lipoprotein lipase (LPL), acyl-
Coa synthetase (ACS), and CD36 [74, 75]. Overexpression
of PPARγ in ﬁbroblasts initiates the adipogenic cascade,
while PPARγ knockout mice are unable to form adipocytes
or adipose tissue [48, 49, 76]. In humans, an activating
mutation in PPARγ leads to increased adipogenesis and
obesity [77]. Another mutation decreasing PPARγ activity
results in lower body mass index [78, 79].
Adipose tissue targets of PPARγ include LPL and fatty
acid transporter FATP in stimulating fatty acid uptake,
malicenzymeinNADPHsynthesisforlipogenesis,phospho-
enolpyruvate carboxykinase in gluconeogenesis, and ACS in
FA esteriﬁcation [16, 80–82]. PPARγ promotes adipocyte
diﬀerentiation of MSCs through various signaling pathways
[83–85]. MSCs can diﬀerentiate into either osteogenic or
adipogenic lineage, depending on the diﬀerentiation cues
(Figure 1). It has been reported that osteogenesis and its
signaling cascade are inhibited by PPARγ activation [86–89].
However, the extent of PPARγ-associated adipogenic stimu-
lation or osteogenic inhibition depends on the nature of the
ligands [90]. Such ligand-dependent regulatory functions of
diﬀerentiation may explain the shift away from osteogenesis
in the aging process, due to an increase in the number of
bone marrow adipocytes, oxidized LDL metabolites, and
fatty acids metabolites.
5. Role of PPARγ inOsteogenesis and
Adipogenesis of MSCs
Osteogenesis and adipogenesis appear to originate from
the same progenitor bone marrow mesenchymal stem cells
(MSCs) [91–93]. MSC diﬀerentiation into osteoblast or
preadipocytes occurs through a complex regulation of events
[91–94]( Figure 1). Bone morphogenetic proteins (BMPs)PPAR Research 5
play an important role in this diﬀerentiation process and
subsequent bone formation [2, 93, 95–101]. BMP-2, BMP-
6, and BMP-9 regulate targets associated with osteoblast dif-
ferentiation, while BMP-2, BMP-4, and BMP-7 appear to be
associated with preadipocyte diﬀerentiation [93, 101–110].
Mice with BMP2-regulated Schnurri-2 knockout showed a
r e d u c t i o ni nw h i t ef a tm a s s[ 111].
PPARγ can stimulate adipocyte diﬀerentiation of MSCs.
PPAR+ blasts (progenitor cells) have been noted in
hematopoeiticlineages,andPPARγ isabletoinduceterminal
diﬀerentiation in monocytes and adipocytes [48, 50, 112,
113]. Overexpression of PPARγ in ﬁbroblastic cells initiates
the adipogenic cascade, while PPARγ knockout mice were
unable to form adipocytes or adipose tissue [48, 49, 76].
In humans, an activating mutation in PPARγ leads to
increased adipogenesis and obesity, while inactivating muta-
tion results in a lower body mass [77–79]. To demonstrate
its importance, no factor has been shown to be able to
induce adipogenesis in the absence of PPARγ and almost
all pathways involved in adipogenesis involve regulation of
PPARγ [114].
Furthermore, in a review by Giaginis et al. PPARγ
agonists were found to have a remarkable role regulating
bone turnover [115]. However, while PPARγ seems to shift
the diﬀerentiation pathway away from osteoblastogenesis
and towards osteoclastogenesis, this is not always the case.
Giaginisetal.reviewedstudiesfocusingonboththesynthetic
andnaturalPPARγ ligandeﬀectsonosteoblastandosteoclast
formation, as well as apoptosis and overall bone formation.
They found divergent results, as it appears there are other
factors that contribute to bone turnover regulated by PPARγ.
For example, since natural ligands are found in both the
diet and the inﬂammatory cascade, perhaps these processes
determine the ﬁnal outcome of PPARγ-regulated bone
turnover. Its eﬀect in clinical studies poses a similar paradox,
while some patients receiving synthetic PPARγ agonists for
Diabetes Mellitus type II experienced bone loss, others were
noted to have a decrease in bone resorption markers [115].
PPARγ plays an intriguing role in both adipogenesis
and osteogenesis. Earlier reports indicate that homozygous
PPARγ deﬁcient progenitor cells spontaneously diﬀerentiate
into osteoblasts via increased osteoblastogenic factors in
vitro,andheterozygousPPARγ deﬁciencyresultsinincreased
in vivo bone formation [87]. However, recent studies have
demonstrated that osteogenic BMPs can eﬀectively induce
adipogenic diﬀerentiation [101, 116, 117]. PPARγ has
been shown to be signiﬁcantly upregulated by osteogenic
BMPs [101, 118]. Overexpression of PPARγ2p r o m o t e s
the osteogenic BMP-induced osteogenesis and adipogenesis
[101]. Silencing PPARγ2 expression leads to an inhibition
of adipogenic diﬀe r e n t i a t i o na sw e l la ss t i m u l a t i o no f
osteogenic diﬀerentiation and osteoid matrix mineralization
[101]. However, it remains to be elucidated how BMP-
induced MSC diﬀerentiation into osteogenesis and adipoge-
nesis diverges.
The regulation underlying these eﬀects could be sec-
ondarytothenuclearcompetitionbetweenPPARγ andother
members of its nuclear receptor superfamily. Regulation
of the osteogenic promoter, osteocalcin, by glucocorticoids,
vitamin D, and thyroid hormone, occurs through the same
nuclear pathway as PPARγ [119–121]. In addition, PPARγ
activation by fatty acids and their derivatives might lead
to a slowing of osteoblast diﬀerentiation, which would
explain the tendency to shift to adipogenesis. These ﬁndings
are intriguing as recent studies have indicated that aging
activates adipogenesis and suppresses osteogenesis, possi-
bly through the increased availability of these fatty acids
and a decrease in metabolic production of many nuclear
hormones. These would shift the signaling towards PPARγ,
which might explain part of the mechanism underlying
osteoporosis [122, 123].
5.1. Side Eﬀects of PPARγ Ligands. In the treatment of Dia-
betes Mellitus (DM) type II with synthetic PPARγ ligands,
themostcommonsideeﬀectsobservedhavebeenheadaches,
gastrointestinal symptoms (nausea, diarrhea), and suscepti-
bility to infections. Troglitazone has been withdrawn from
the market secondary to its hepatic toxicity; however, this
appears to be drug speciﬁc and not universal amongst PPAR
agonists.
In a review by Mudaliar and Henry about the clinical use
of glitazones, side eﬀects include edema, weight gain, and
mild drops in hematocrit. Rarely, increases in liver enzymes
are observed. These synthetic PPARγ agonists induce the
cytochrome P450 isoform CYP3A4 in the liver, aﬀecting the
metabolism of many other drugs. These drugs have been
shown to increase plasma volume, thus, leading to edema
and a dilutional drop in hematocrit. While the mecha-
nism has not been elicited, PPARγ agonists antagonize the
vasoconstrictioninducedbyhyperinsulinemia,bysensitizing
cells to the eﬀects of insulin. Therefore, they relax vascular
smooth muscles and decrease peripheral blood pressure.
While there is no mention of increased peripheral adipose
tissue, the propensity of PPARγ to induce lipid storage might
underlie the observed weight gain [124].
Theoretically, a shift away from osteogenesis and towards
adipogenesis might also promote osteoporosis and increase
fracture risk. This has been demonstrated in a prospective
study of over 80,000 patients being treated for DM type II
[125]. Furthermore, competition for the RXR heterodimer
might decrease the eﬀects of other nuclear receptors in the
superfamily, having a variety of eﬀects on many diﬀerent tis-
sues. While recently there was a report suggesting increased
fracture risk in patients receiving PPARγ agonists, there has
been relatively little other evidence supporting any of these
notions [122].
6. Molecular Biology of Osteosarcoma
The molecular pathogenesis underlying OS development is
poorly understood. OS is associated with aberrations in p53
and Rb expression [1, 2, 126–128]. Other genetic alterations
associated with OS development include p16INK4a, c-Myc,
Fos-Jun, MDM2, CDK4, and cyclin D [1, 2, 126]. Altered
cell signaling pathways in OS include Wnt, sonic hedgehog,
TGFβ/BMP families, and IGF2 [1, 2, 126]. Mutations in
DNA helicase increase OS risk and MMP expression leads6 PPAR Research
t oam o r ea g g r e s s i v eO St u m o r ,w h i l el a c ko ft e l o m e r a s e
activity is associated with a favorable prognosis [129–131].
The identiﬁable risks associated with OS include exposure
to the FBJ or SV40 virus, beryllium oxide chemical, and
radiation [132–134].
Disruption of the osteogenic diﬀerentiation pathway
from MSCs is thought at least in part to be responsible
for OS tumorigenesis [2, 7, 9, 10]( Figure 2). By preventing
the diﬀerentiation of MSCs, the proliferative capability of
preosteoblasts increases the risk for malignant transforma-
tion. It has been well established that early progenitor cells
have similar characteristics to a variety of tumor cells. For
example, progenitor cells of the hematopoietic system share
similar leukocyte receptors to leukemic cells. Furthermore,
tumor cells share many of the antiapoptotic and self renewal
machinery with stem cells [135]. It has been proposed that
a small subset of cancer cells, known as cancer stem cells,
act in a similar manner to adult stem cells, with proliferative
and regenerative capabilities that enable tumors to survive
a n dg r o w[ 135]. In colon cancer cells, preneoplasia and
neoplasia have the same nuclear morphotypes that 5–7-
week-old fetal gut stem cells possess but are not found in
theadultcoloniccryptcells[136].Osteosarcomacellsdisplay
similar characteristics to undiﬀerentiated osteoblasts [7–10].
In OS cell lines, early osteogenic markers, such as CTGF, are
highwhilelatemarkerssuchasRunx2,AlkalinePhosphatase,
Osteopontin, and Osteocalcin are low [7].
Therefore, investigation into the induction of terminal
diﬀerentiation in cells with such diﬀerentiation defects has
increased in recent years. A similar process has been reported
in Ewing’s Sarcoma, in which silencing the EWS/FLI-1
in Ewing’s sarcoma cells leads to their recovery of MSC
capability to diﬀerentiate into osteogenic lineages [137].
Accordingly, overexpression of this oncogene causes MSCs
to remain in an undiﬀerentiated state and promotes tumor
growth [138]. Rb mutations occur in many OS tumors
[1, 2, 126–128]. Rb coactivates the osteoblast diﬀerentiating
agent Runx2 and loss of function of Rb stalls terminal
osteoblast diﬀerentiation [139]. Furthermore, it has been
recently shown that OS cells are refractory to BMP-induced
osteogenic diﬀerentiation, whereas osteogenic BMPs pro-
mote OS growth in vivo, which can be overcome by intro-
ducing key osteogenic regulator Runx2 [7]. These ﬁndings
suggest that the late stages of osteogenic diﬀerentiation may
be preserved [7, 8]. Therefore, anti-OS therapies may be
developed by promoting osteogenic terminal diﬀerentiation
[2, 7]. Diﬀerentiation agents would add another dimension
to the current chemotherapeutic cocktails focusing on the
inhibition of the cell cycle.
6.1. Molecular Biology Relating to the Diﬀerentiation Status in
Tumors. It appears that the diﬀerentiation status not only is
responsible for the development of OS but also may predict
its malignant potential. From the early 1970s when the idea
of diﬀerentiation was ﬁrst proposed, to more recently when
diﬀerentiationagentsareusedforcertaincancerphenotypes,
it has been observed that this process is associated with many
morphological changes in the respective cells. These changes
leading to a well-diﬀerentiated cell include repression of
responsiveness to growth factors, withdrawal from the cell
cycle into a state of quiescence, and a decreased ability to
re-initiate proliferation [140]. For example, as adipocytes
diﬀerentiate, they progressively become less responsive
to mitogenic growth factors MIX and PDGF, eventually
repressing the expression of proto-oncogenes c-jun and
junB [141, 142]. The more diﬀerentiated the adipocyte, the
less responsive it is to growth factors. Terminal adipocyte
diﬀerentiation is accompanied by expression of proteins that
repressRNAexpression,alongwithinductionofp21,leading
to irreversible loss of proliferative potential [140,143]. When
breast cancer’s estrogen receptors were ﬁrst discovered and
evaluated, the notion was proposed that the cancers with
estrogen receptors represent a well-diﬀerentiated class of
tumors that undergo clonal evolution and eventually lose
their receptor status when they become poorly diﬀerentiated
[144]. Another example occurs when Simian Virus 40 large
T antigen transforms cells to increase their responsiveness to
growth factors and become undiﬀerentiated [145].
The fundamental idea behind diﬀerentiation therapy
for tumors is that by inducing terminal diﬀerentiation,
the tumor cells lose their proliferative phenotypes. Diﬀer-
entiation causes cells to lose their proliferative potential
and repress their responsiveness to growth factors, while
at the same time possibly increasing their susceptibility
to apoptosis, induction of tumor suppressors, repression
of oncogenes, inhibition of angiogenesis, and induction of
cytotoxic agents. As cells become more diﬀerentiated, these
changes make them less aggressive and more responsive to
other chemotherapeutic agents.
6.2. Clinical Examples of Therapeutic Success by Induction
of Terminal Diﬀerentiation. Inhibition of tumor growth
through diﬀerentiation therapy has been demonstrated in
clinical cases of hematologic and breast tumors. Induction
of terminal diﬀerentiation was ﬁrst shown to be successful
in treating AML with low-dosage araC [146]. Recently, there
have been many more therapeutic interventions that have
focused on overcoming the uncontrolled cell proliferation
through terminal diﬀerentiation [8, 9, 11–13]. One possi-
bility deals with the nuclear receptor superfamily associated
with vitamin D3, thyroid hormone, glucocorticoids, sex hor-
mones, retinoids, and orphan receptors [14–17]. Treatment
focusing on counteracting hormone dependent activation of
these nuclear receptors is seen in therapies such as tamoxifen
for breast cancer [18]. In this and other examples, regulation
of the nuclear receptor leads to diﬀerentiation, causing the
cells to lose their proliferative properties and antiapoptotic
tendencies.
7. Role of PPARs in Tumorigenesis and
Differentiation
PPARs play an important role in tumorigenesis and dif-
ferentiation (Table 1). PPARα is responsible for hepatocar-
cinogenic eﬀects in rodents [147]. PPARβ was identiﬁed
as a downstream target of the APC/β-catenin pathway,PPAR Research 7
associated with human colon tumors [54]. PPARβ has
been shown as a target for nonsteroidal anti-inﬂammatory
drug- (NSAID-) induced chemopreventive eﬀects in colon
cancer [45, 54]. High dose of NSAIDs, such as sulindac
and indomethacin, displays chemopreventive eﬀects in the
familial adenomatous polyposis mouse model. It downreg-
ulates Cox-2 expression in humans, leading to a decrease
in intestinal polyps, inhibition of cell cycle progression, and
induction of apoptosis in colorectal tumor cells [45, 148,
149]. NSAIDs can disrupt the ability of PPARβ to bind to
its peroxisome proliferator response elements (PPREs) in
vitro, while PPARβ overexpression was able to rescue NSAID
induced apoptosis in colon tumor cells [45]. These ﬁndings
mayexplainthecorrelationbetweendietaryfatconsumption
and colon cancer incidence, since fatty acids can serve as
ligands for PPARβ.
PPARγ has shown promise in therapy promoting termi-
nal diﬀerentiation and apoptosis in a variety of malignan-
cies, including liposarcoma, breast cancer, leukemia, gastric
cancer, non−small cell lung cancer, and prostate cancer
[19–27]. In humans, the treatment of end stage prostate
cancer with PPARγ synthetic ligand troglitazone leads to
prostate speciﬁc antigen (PSA) stabilization [150]. Although
these results are promising, there are many examples of
contradictory roles of PPARγ in tumorigenesis. It has been
observed that while PPARγ agonists inhibit growth and
induce apoptosis in both breast tumor cells and leukemic
cells, administration of PPARγ antagonists enhanced this
tumorgrowthinhibitoryeﬀect[151,152].Thefusionprotein
EWSRI/NR4A3 in extraskeletal chondrosarcomas activates
PPARγ expression [153]. In ﬁbrosarcoma cells, the synthetic
PPARγ agonist ciglitazone induces tumor cell invasion
through the generation of ROS and ERK [154].
This controversy is best exempliﬁed by the role of
PPARγ in colorectal tumorigenesis. PPARγ agonists have
been shown to promote mouse intestinal tumors, while
loss of function mutations of PPARγ has been identiﬁed
in human colon tumors [30, 45, 150]. Synthetic PPARγ
agonists promote the development of colon tumors in mice
with a mutation in the tumor suppressor APC [29, 30].
This leads to increased levels of B-Catenin. Furthermore,
mice diets high in saturated fats promotes tumorigenesis
[155]. PPARγ activation by Fas could explain the link
between high fat diets and colon cancer. However, one
study disputed the PPARγ agonist role in tumor promotion,
as it showed that PPARγ agonists were able to induce
diﬀerentiation and inhibit human tumors from growing in
nude mice [31]. Furthermore, PPARγ agonists are able to
induce diﬀerentiation, cell cycle arrest, and apoptosis in
human colon cancer cell lines [31]. The anti-inﬂammatory
eﬀects of PPARγ lead to a reduced number of cancer
precursor foci in inﬂammatory bowel disease [156]. One
possible explanation for the antagonistic role of PPARβ
and PPARγ in colon tumorigenesis may be competition for
RXR heterodimerization. The cellular proliferation caused
by PPARβ, induced by speciﬁc ligands, may lead to over-
expression and inhibition of PPARγ heterodimerization,
and subsequently contribution to human colon cancer
development.
Thesecontradictoryresultsmightbeexplainedbyspecies
speciﬁc eﬀects, where a combination of the diﬀerent factors
within each animal leads to diﬀerent PPARγ-associated
signaling outcomes. Another example of the diﬀerences
between species occurs in hepatic cancers. PPARγ agonists
are seen as potent carcinogens in rodents, but not seen
in humans or primates [157, 158]. Furthermore, PPARγ
agonist rosiglitazone seems to enhance carcinogenic eﬀects
oftheurinarybladderinrodents,whiletreatmentofdiabetes
with pioglitazone in humans does not seem to increase the
incidence of these or any other tumors [159].
While the mechanisms underlying PPARγ action are
not fully established, it has been shown that PPARγ can
inhibit the cell cycle, which is accomplished at least in
part through downregulating the protein phosphatase PP2A
upon PPARγ activation [160]. The PPARγ ligands can also
inhibit the G1/S transition by inhibiting Rb phosphorylation
[161]. Furthermore, PPARγ upregulates the CDK inhibitors
p18 and p21 [162]. PPARγ ligand PGJ2 induces both CDK
p21 and the proapoptotic Bax but downregulates the anti-
apoptotic Bcl-xL [163]. Synthetic PPARγ agonist treatment
in human pancreatic cancer and bladder cancer cell lines
resulted in G1 cell cycle arrest secondary to p21 induction
[164, 165]. Further insight into the cross-talk between these
diﬀerent mechanisms will guide future antitumor therapies.
8. Antitumor Activityof PPARγ Agonists in
Osteosarcoma
Increasing evidence suggests that activation of PPARγ may
be explored as a possible intervention in osteosarcoma
(Table 2). PPARγ agonists are thought to induce terminal
diﬀerentiation in adipogenesis. OS cells share many char-
acteristics to undiﬀerentiated osteoblasts [7–10]. Therefore,
modulators that are able to promote the diﬀerentiation of
these immature osteoblasts should have similar eﬀects on
the OS cells. PPARγ agonist rosiglitazone has been shown
to inhibit osteoblast proliferation, leading to decreased
osteogenesis [88, 166] .Ar e c e n ts t u d ys h o w e dP P A R γ to
be a critical mediator underlying doxorubicin resistance in
OS cell lines [167]. The chemoresistant OS cell lines were
showntohaveanincreasedexpressionofIL-8,whichinduces
the antiapoptotic KLF2 [167, 168]. KLF2 is thought to
negatively regulate the PPARγ-induced expression of C/EBP
and ADD1/SREBP, suggesting that the drug resistance may
occur through the inhibition of PPARγ-induced apoptosis.
Furthermore,theNSAID-AssociatedGene1(NAG-1),which
is associated with NSAID-induced apoptosis, has been
upregulated by PPARγ in canine OS cell lines [169].
PPARγ agonists and 9-cis-retinoic acid have the capa-
bility to induce osteoblastic diﬀerentiation of OS cells and
inhibit OS proliferation [9, 32]. After exposure to these
agents, not only did the OS cells show decreased proliferative
capabilities and susceptibility to apoptosis but they also
expressed increased diﬀerentiation markers, such as alkaline
phosphatase. Therefore, it appears that such agents would be
useful in preventing recurrence and metastasis after surgical
removal of osteosarcoma. The results are further supported8 PPAR Research
Table 1: Basic features of the three PPAR isoforms.
Location Ligands Coactivators Primary function Knockout
PPARα
liver, brown fat,
kidney, heart, skeletal
muscle
ﬁbrates fatty acids
(e.g., oleic acid,
palmitic acid)
eicosanoids (e.g.,
arachidonic acid)
p300, c/EBP,
SRC-1, PBP,
PGC-1, PRIP
lipid catabolism,
inﬂammatory
responses,
lipoprotein
metabolism
hepatomegaly, liver
tumors, impaired
wound healing,
prolonged
inﬂammatory
responses, increased
adipose tissue
PPARδ gut, kidney, brain,
heart, skeletal muscle
fatty acids,
NSAIDS
(antagonist)
SRC-1, PBP
fatty acid
β-oxidation, bone
metabolism,
tumorigenesis,
vascular integrity
fatal placental defects
from abnormal
vasculature, small
healthy adults
PPARγ
adipose tissue,
cartilage, osteoblasts,
epithelial cells,
prostate, large
intestine, monocytes,
kidney
thiazolinediones
eicosanoids (e.g.,
15d-PGJ2,
15-HETE) fatty
acids (e.g., DHA,
linoleic acid)
p300, c/EBP,
SRC-1, PBP,
PGC-1, PRIP
adipogenesis,
inﬂammatory
response, insulin
sensitization,
diﬀerentiation
embryo-fatal,
placenta fails to
implant and develop,
severe metabolic,
hepatic, intestinal,
adipogenic,
abnormalities
by the ability of PPARγ to induce apoptosis in chondrosar-
coma cells [177]. However, one study by Lucarelli et al.
showed that treatment of human osteosarcoma cells with the
PPARγ agonist troglitazone promotes the in vitro survival
via reduction in apoptosis of the malignant cells [170].
Although the mechanisms accounting for this diﬀerence are
not known, it is likely that this molecular complexity results
from the nuclear cross-talk and interplays between PPARγ
and other nuclear receptor hormones. It is plausible that
the eﬀects of PPARγ agonists on OS are largely dependent
on which step in the diﬀerentiation pathway the defect has
occurred (Figure 2). Downstream defects may be resistant
to PPARγ agonists-induced terminal diﬀerentiation of its
upstream counterparts. The speciﬁc factors that participate
in the nuclear signaling and transcriptional regulation,
along with the diﬀerentiation molecules associated with OS
tumorigenesis, have yet to be fully elicited.
To the best of our knowledge, there have been no studies
examining the eﬀects of PPARγ on the metastatic potential
in OS. However, our notion of the potential for PPARγ to
reduce metastatic potential of OS is supported by examples
in other tumors. Rosiglitazone has been shown to decrease
the number of lung metastasis of mammary tumors in mice
[178]. Dietary administration of PPARγ ligands linoleic acid
and conjugated linoleic acid inhibited peritoneal metastasis
of colorectal tumors in nude mice [179]. Furthermore,
Pioglitazone inhibited colon tumor liver metastasis in mice,
possibly by downregulating Cox-2 and cyclin D1 [180].
These anti-inﬂammatory and other possible antiangiogenic
eﬀects of PPARγ extend its potential as a chemotherapeutic
agent beyond diﬀerentiation. Overexpressing PPARγ in
nonsmall cell lung cancer cells inhibited tumor number and
metastasis [181]. Due to its ability to inhibit angiogenesis,
tumor cell invasion, and inﬂammation, it therefore follows
that PPARγ would inhibit metastasis. In an analysis of
primary breast tumors, PPARγ expression was more often
in low-grade than high-grade tumors, associated with a
more favorable survival, and decreased in tumor relapses
[182]. PPARγ ligand troglitazone inhibited growth and liver
metastasis of papillary thyroid tumors [183].
9. SynergisticAntitumorActivitybetween
PPARγ Agonists andRetinoids in
Osteosarcoma
Receptors for retinoids include retinoic acid receptors
(RARs) and retinoid X receptors (RXRs). RARs are activated
by all-trans retinoic acid, a vitamin A metabolite, and het-
erodimerizes with RXR after ligand binding. RARs have been
implicated in early embryonic morphogenesis, including
development of the forebrain, hindbrain, and body axis, as
well as, early signaling associated with the pancreas, heart,
eye, lung, and genitourinary tracts [184–186]. Furthermore,
it is able to induce the diﬀerentiation of many cancer cells
a n di su s e da sa ne ﬀective therapy in the treatment of acute
p r o m y e l o c y t i cl e u k e m i ab yd i ﬀerentiating cells that express
the PML-RARα fusion protein [9, 32, 45, 187–189].
RXRs are activated by 9-cis retinoic acid. Beyond the
ability of RXR to heterodimerize with many members of
t h en u c l e a rr e c e p t o rs u p e r f a m i l y ,s u c ha sP P A R s ,R X R sc a n
form homodimers. RXRs play important roles in signaling
pathways associated with development and carcinogenesis.
We have recently demonstrated that exogenous expression of
RARα induces ligand-independent myogenic diﬀerentiation
from progenitor cells [190]. We have also found that all-
trans retinoic acid and 9-cis retinoid acid can eﬀectively
inducethediﬀerentiationofmousefetalliver-derivedhepatic
progenitor cells [191]. RXRs are overexpressed in breast
ductal carcinomas, its ablation leads to prostate and skin
hyperplasia, and its overexpression sensitizes tumors to
rexinoid family diﬀerentiation agents [192–195]. A syntheticPPAR Research 9
Table 2: Potential eﬀects of nuclear receptor ligands on osteosarcoma tumors.
Ligand Experimental Setup Eﬀect Mechanism Reference
PPARγ
Troglitazone in vitro proliferation
and apoptosis assays
inhibited
proliferation
promotion of
apoptosis, induce
diﬀerentiation
(alkaline
phosphatase)
Haydon 2002, 2007
[9, 32]
Ciglitazone in vitro proliferation
and apoptosis assays minimal eﬀect unknown Haydon2002 [32]
Troglitazone
in vitro MTT
proliferation and
apoptosis assays
increased
proliferation
inhibition of
apoptosis
Lucarelli 2002
[170]
Pioglitazone and
PG J(2)
in vitro MTT and
apoptosis assays of
Chondrosarcoma
Cells
inhibition of
proliferation promoted apoptosis Nishida [171]
Retinoic Acid 9-cis retinoic acid in vitro proliferation
and apoptosis assays
inhibited
proliferation
promotion of
apoptosis
Haydon 2002, 2007
[9, 32]
Estrogen
17-beta estradiol,
Ospemifene
U2OS expressing ER,
in vitro apoptosis
assays
opposed
Etoposide-induced
cell death
oppose increases in
IL-6 and decreases in
OPG, preventing
osteoclast activation
Kallio 2008 [172]
Tamoxifen,
Raloxifene
U2OS expressing ER,
in vitro apoptosis
assays
no eﬀect on
Etoposide-induced
cell death
unknown Kallio 2008 [172]
17-beta estradiol,
SERMS (genistein,
daidzein)
U2OS expressing ER,
in vitro cell cycle,
proliferation,
apoptosis assays
inhibit
proliferation,
promote apoptosis
decrease EGFR,
increased osteoblast
maturation markers
Salvatori 2009
[173]
Vitamin D
1-alpha
hydroxyvitamin D3
oral administration in
Dunn murine OS
model
inhibits tumor
growth and
metastasis
increased necrosis, no
cell cycle mitotic
index eﬀects
Hara 2001 [174]
Prolactin + 1,25
(OH)2 Vitamin D3
RT-PCR, western
blots
PRL inhibits VDR
expression in
response to 1,25
(OH)2 Vitamin D3
VDR expression is
dependent on BRCA1
expression
Deng [175]
calcitriol
OS cells with
increased RXR
degradation, treated
with calcitriol
increased
expression of RXR
restores
anti-proliferative
eﬀects of calcitriol
calcitriol induced
degradation is
dependent on RXR
expression
Prufer 2002 [176]
rexinoidbexatronehasbeendevelopedforuseinchemother-
apeuticcocktailsinmicemammarytumors,aswellashuman
cutaneous T-cell lymphoma, with partial responsiveness in
nonsmall cell lung cancer [196–198].
A comprehensive analysis of the possible synergistic
eﬀects between PPARγ and retinoids has been carried out
in a panel of OS cell lines (Table 2)[ 9, 32]. As a single
agent, PPARγ ligand troglitazone was shown to be the most
eﬀective in inducing cell death, followed by 9-cis retinoic
acid [9, 32]. The strong synergistic eﬀect on the induction
of cell death was observed when both troglitazone and 9-
cis retinoic acid or ciglitazone and 9-cis retinoic acid were
administered to osteosarcoma cells [9, 32]. Troglitazone was
shown to eﬀectively induce alkaline phosphatase activity, a
well-characterized hallmark for osteoblastic diﬀerentiation
[9, 32]. These ﬁndings suggest that PPARγ and/or RXR
ligands may be used as eﬃcacious adjuvant therapeutic
agentsforosteosarcomaaswellaspotential chemopreventive
agents for preventing the recurrence and metastasis of
osteosarcoma after the surgical removal of the primary
tumors.
10.Other NuclearReceptors inOsteosarcoma
Except for PPARs and retinoid receptors, several members
of the nuclear receptor superfamily are also involved in the
cell signaling and diﬀerentiation processes associated with
OS (Table 2). Estrogens and selective estrogen receptor mod-
ulators (SERMs) are able to induce terminal diﬀerentiation
in osteosarcoma cell lines through the downregulation of
EGFR [173]. EGFR is a critical mediator of cell proliferation
and diﬀerentiation, whose expression decreases over the10 PPAR Research
course of osteoblast diﬀerentiation and maturation [199,
200]. The stimulation of estrogen receptors leads to the
downregulation of EGFR in OS, resulting in cell cycle
inhibition and apoptosis. Alternatively, the estrogen 17 β-
estradiol protected osteosarcoma cells expressing estrogen
receptors from etoposide-induced apoptosis [172]. However,
the selective estrogen receptor modulators (SERMs) tamox-
ifen and raloxifene have no antiapoptosis eﬀects.
Vitamin D receptor (VDR) has also been shown to play
a role in OS cell lines and their responsiveness to therapeutic
interventions. VDR is overexpressed on some OS cell lines
and administration of 1, 25-dihydroxyvitamin D3 inhibits
tumor growth and metastasis, while promoting terminal
diﬀerentiation [174, 201]. Interestingly, it has been reported
that the upregulation of VDR in OS cell lines is dependent
on the tumor suppressor BRCA1 [202]. Although a synthetic
VDR ligand calcitriol is able to exert antiproliferative eﬀects
in OS cells, this process is dependent on the expression of
RXRs. Degradation or downregulation of RXRs causes OS
resistancetotheantitumoreﬀectofcalcitriol[176].Thus,the
anti-OS activity of VDR is dependent on many other nuclear
proteins, including BRCA1 and RXRs.
11. Concluding Remarks
OS is the most frequent primary bone sarcoma, comprising
approximately 20% of all bone tumors and about 5% of
pediatric tumors overall. OS tumors display a broad range of
genetic and molecular alterations, including the gains, losses,
or arrangements of chromosomal regions, inactivation of
tumor suppressor genes, and the deregulation of major
signaling pathways. However, except for p53 and/or RB
mutations, most alterations are not constantly detected
in the majority of osteosarcoma tumors. Recent studies
strongly suggest that OS may be regarded as a diﬀerentiation
disease that is caused by genetic and epigenetic disruptions
of osteoblast terminal diﬀerentiation. It has been well
established that PPARs and retinoids play an important role
in regulating osteogenic diﬀerentiation of MSCs. Increasing
evidence indicates that PPAR agonists and/or retinoids can
inhibit cell proliferation and induce apoptosis in cancer
cells, including OS cells. PPAR agonists and/or retinoids may
also inhibit OS growth by promoting osteoblastic terminal
diﬀerentiation. One of the future directions is to develop
safe and eﬀective PPAR agonists and/or retinoid derivatives.
These agents can be then used as adjuvant therapeutic drugs
for OS therapy. Meanwhile, more thorough investigations
will be needed to examine the potentially beneﬁcial and/or
adverse eﬀects of PPARγ ligands on diﬀerent cells in bone
and bone marrow microenvironment. Furthermore, these
agentscanbeusedaschemopreventiveagentsforthepatients
with OS who undergo the resection of the primary bone
tumors in order to prevent local recurrence and/or distal
pulmonary metastasis.
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